Jacinto JE, Cisneros-Gómez S, Arevalo-Simental D, Ontiveros DO, Cortes-Quezada S, Mendoza-Adam G, Roig-Melo EA

Language: Spanish
References: 16
Page: 25-31
PDF size: 546.36 Kb.

ABSTRACT

Introduction. Diabetic retinopathy is the leading cause of visual impairment in adults over the age of forty. Diabetic macular edema is the main cause of moderate visual loss in patients with diabetic retinopathy. It is estimated that 20% of patients with diabetic retinopathy suffer from it. Expression of vascular endothelial growth factor (VEGF) and inflammation play a key role in the pathogenesis of the disease.
Objective. To evaluate the efficacy and safety of the combination of intravitreal anti-VEGF/steroid for the treatment of diabetic macular edema with central involvement. Material and Methods. We reviewed the medical records of patients diagnosed with diabetic macular edema who were treated with a combination of intravitreal anti-VEGF/steroid.
Results. A total of 17 patients with macular edema were included. Follow-up was assessed at 24 weeks. An improvement in 28-letter visual acuity was observed on average, a reduction of 158 µm in central macular thickness and an increase in intraocular pressure of 1 mmHg. One of the patients underwent cataract surgery and one patient had increased intraocular pressure of more than 10 mmHg which was controlled with the addition of an ocular hypotensive.
Conclusions. The combination of intravitreal anti-VEGF/steroid improved visual acuity, significantly reduced central macular thickness and did not significantly increase intraocular pressure in patients with diabetic macular edema. No serious adverse effects were found with the use of intravitreal anti-VEGF/steroid combination in this series at 24 weeks.

REFERENCES

1. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552–63.

2. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64.

3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1–32.

4. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73–9.

5. Lang GE, Lang SJ: Clinical treatment of diabetic macular edema. Klin Monatsbl Augenheilkd 2011; 228:R1–R11.

6. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt láser for diabetic macular edema. Ophthalmology 2010; 117:1064-77.

7. Chang-Lin JE, Aittar M, Acheampon AA, et al. Pharmacocokinectics and pharmacodybamics of a sustain realease dexametasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;118: 52: 80-6.

8. Boyer et al. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology 2014;121: 10: 1904-14.

9. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2). Ophthalmology 2010;117:2146-51.

10. Elman Mj, Quin H, Aiello LP, et al, Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-8. 11.Rajendram R, Fraser-Bell S, Kaines A, et al. A 2 year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-9. 12.Do DV, Nguyen QD, Boyer D, et al, DA VINCI Study Group. One-Year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.

11. 13.Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103:1796–806.

12. 14.Antcliff RJ, Marshall J. The pathogenesis of edema in diabeticmaculopathy. Semin Ophthalmol. 1999;14:223–32.

13. 15.Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13:1275–93. 16.Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–2. 17.Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.

14. 18.Al Rashaed S, Arevalo JF. Combined Therapy for Diabetic Macular Edema. Middle East Afr J Ophthalmol. 2013; 20(4):315-320.

15. 19.Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801.

16. 20.Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh. Intravitreal b eva c i zuma b ve rsus comb ined b eva c i zuma b - triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008; 18(6):941- 8.